Clinical Trials Logo

Clinical Trial Summary

The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Certolizumab Pegol (CZP) in subjects with active axial Spondyloarthritis (axial SpA).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01087762
Study type Interventional
Source UCB Pharma
Contact
Status Completed
Phase Phase 3
Start date March 2010
Completion date August 2015

See also
  Status Clinical Trial Phase
Completed NCT00768950 - The Characterization of Small Bowel and Colonic Involvement in Patients With Seronegative Spondyloarthritides N/A
Recruiting NCT03839862 - Faecal Analyses in Spondyloarthritis Therapy
Recruiting NCT06369324 - Efficacy of Pain Neuroscience Education and Physiotherapy in Patients Diagnosed With Spondyloarthritis N/A
Completed NCT03327454 - Benepali® PEN Patient Satisfaction Survey